TRIM56 and metabolic dysfunction-associated steatotic liver disease: The study experimentally demonstrated that TRIM56 promotes the degradation of FASN via the proteasomal pathway by catalyzing K48-linked ubiquitination, thereby suppressing FASN protein expression and downstream lipid synthesis to delay the progression of NAFLD (121).